<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9923">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687422</url>
  </required_header>
  <id_info>
    <org_study_id>2021-I2M-C&amp;T-B-093</org_study_id>
    <nct_id>NCT05687422</nct_id>
  </id_info>
  <brief_title>Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy</brief_title>
  <official_title>A Randomized Controlled Study of Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular&#xD;
      area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in&#xD;
      treating chronic CSC is proved to be safe and effective. However, some studies indicate that&#xD;
      it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including&#xD;
      us, think that this may be related to micropulse laser parameters. Thus we need to explore&#xD;
      better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to&#xD;
      compare the treatment effect of two different patterns of laser parameters (small and regular&#xD;
      spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial,&#xD;
      by comparing the subretinal fluid regression ratio, central retinal thickness, macular&#xD;
      microvisual field, macular vascular density, chroidal volume changes and visual acuity of two&#xD;
      groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy&#xD;
      of refined micropulse laser in treating chronic CSC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subretinal fluid regression ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing the subretinal fluid regression ratio of two groups at 6 months follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central retinal thickness changes</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing the central retinal thickness changes of two groups at 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>100μm laser spot diameter group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200μm laser spot diameter group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>100μm laser spot diameter micropulse laser</intervention_name>
    <description>100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months</description>
    <arm_group_label>100μm laser spot diameter group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>200μm laser spot diameter micropulse laser</intervention_name>
    <description>200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months</description>
    <arm_group_label>200μm laser spot diameter group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age range 18-50 years&#xD;
&#xD;
          -  Patients diagnosed with chronic Central serous chorioretinopathy&#xD;
&#xD;
          -  Patients have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of other fundus diseases or refractive media opacity&#xD;
&#xD;
          -  Patients have underwent other treatment methods for chronic Central serous&#xD;
             chorioretinopathy&#xD;
&#xD;
          -  Diopter&gt;-6D&#xD;
&#xD;
          -  A history of system diseases such as hypertension or diabetes&#xD;
&#xD;
          -  A history of using local or systemic corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 25, 2022</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Yu Xiaobing</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

